In a letter published in the Observer newspaper, 93 signatories, including the Association of the British Pharmaceutical Industry (ABPI), have come out against Brexit, citing the negative effect it will have on the life sciences industry and UK-based patients. In their letter, the industry leaders say: â€œThe life-science sector makes an important contribution to the health and wealth of the UK. The sector employs over 222,000 people across the UK. It spends Â£4bn on R&D, and also attracts high levels of inward investment â€“ government support has led to some Â£6bn in the last five years alone.â€ They say the case for continuing in the EU is clear. â€œContinued UK membership of the EU will also benefit scientific activity and R&D jobs. UK researchers and small businesses will continue to benefit from access to EU funding and from collaborations with cutting-edge science across the continent. â€œThis will help the UK to continue to attract investment for the R&D activities that will help to discover and develop the next generation of treatments for cancer, respiratory disease and Alzheimerâ€™s, and to continue pioneering work in new vaccines and antibiotics.â€ Campaigners in favour of Brexit have claimed that the NHS will be under threat if the UK remains inside the EU because a massive EU/US trade deal, the Transatlantic Trade and Investment Partnership, will mean health services have to compete with private health providers from the US and Europe.